Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic iron overload

Proteomics

Volumn 14, Issue 9, 2014, Pages 1107-1115

  Montaldo, Claudia ^a,b   Mattei, Simone ^a,c   Baiocchini, Andrea ^b   Rotiroti, Nicolina ^b   Nonno, Franca Del ^b   Pucillo, Leopoldo Paolo ^b   Cozzolino, Angela Maria ^a   Battistelli, Cecilia ^a   Amicone, Laura ^a   Ippolito, Giuseppe ^b   van Noort, Vera ^c   Conigliaro, Alice ^a   Alonzi, Tonino ^b   Tripodi, Marco ^a,b   Mancone, Carmine ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Biomedicine; Hepatic iron overload; Hepatitis C infection; Liver fibrosis; Vitronectin

Indexed keywords

CD98 ANTIGEN; CYTOKERATIN 8; GUANINE NUCLEOTIDE BINDING PROTEIN; IRON; VITRONECTIN; BIOLOGICAL MARKER; MEMBRANE PROTEIN;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMORBIDITY; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRON DEPLETION; IRON OVERLOAD; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; STELLATE CELL; CELL LINE; ISOTOPE LABELING; LIVER CIRRHOSIS; MALE; METABOLISM; UPREGULATION;

BIOLOGICAL MARKERS; CELL LINE; HEPATITIS C; HUMANS; IRON OVERLOAD; ISOTOPE LABELING; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; PROTEOMICS; UP-REGULATION; VITRONECTIN;

EID: 84898630514     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300422     Document Type: Article

References (41)

1. Bataller, R., Brenner, D. A., Liver fibrosis. J. Clin. Invest. 2005, 115, 209-218.
2. Ly, K. N., Xing, J., Klevens, R. M., Jiles, R. B. et al., The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012, 156, 271-278.
3. Marcellin, P., Asselah, T., Boyer, N., Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36, S47-S56.
4. Feld, J. J., Liang, T. J., Hepatitis C-identifying patients with progressive liver injury. Hepatology 2006, 43, S194-S206.
5. Farinati, F., Cardin, R., De Maria, N., Della Libera, G. et al., Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995, 22, 449-456.
6. Nishina, S., Hino, K., Korenaga, M., Vecchi, C. et al., Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008, 134, 226-238.
7. Corengia, C., Galimberti, S., Bovo, G., Vergani, A. et al., Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. Am. J. Clin. Pathol. 2005, 124, 846-853.
8. Tung, B. Y., Emond, M. J., Bronner, M. P., Raaka, S. D. et al., Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003, 124, 318-326.
9. Fujita, N., Sugimoto, R., Urawa, N., Araki, J. et al., Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 2007, 22, 1886-1893.
10. Angelucci, E., Muretto, P., Nicolucci, A., Baronciani, D. et al., Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002, 100, 17-21.
11. Sumida, Y., Yoshikawa, T., Okanoue, T., Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol. Res. 2009, 39, 213-222.
12. Dongiovanni, P., Fracanzani, A. L., Fargion, S., Valenti, L., Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 2011, 55, 920-932.
13. Lee, K. S., Buck, M., Houglum, K., Chojkier, M., Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through cmyb expression. J. Clin. Invest. 1995, 96, 2461-2468.
14. Deugnier, Y., Turlin, B., Pathology of hepatic iron overload. Semin. Liver. Dis. 2011, 31, 260-271.
15. Isom, H. C., McDevitt, E. I., Moon, M. S., Elevated hepatic iron: a confounding factor in chronic hepatitis C. Biochim. Biophys. Acta 2009, 1790, 650-662.
16. Kato, T., Furusaka, A., Miyamoto, M., Date, T. et al., Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 2001, 64, 334-339.
17. Wakita, T., Pietschmann, T., Kato, T., Date, T. et al., Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791-796.
18. Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S. et al., Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102, 9294-9299.
19. Van Lenten, B. J., Prieve, J., Navab, M., Hama, S. et al., Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J. Clin. Invest. 1995, 95, 2104-2110.
20. Mancone, C., Montaldo, C., Santangelo, L., Di Giacomo, C., Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection. J. Proteome Res. 2012, 11, 2786-2797.
21. Medina, I., Carbonell, J., Pulido, L., Madeira, S. C. et al., Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res. 2010, 38, W210-W213.
22. Carpenter, B., McKay, M., Dundas, S. R., Lawrie, L. C. et al., Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br. J. Cancer 2006, 95, 921-927.
23. Deugnier, Y. M., Loréal, O., Turlin, B., Guyader, D. et al., Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 1992, 102, 2050-2059.
24. Geiger, T., Wisniewski, J. R., Cox, J., Zanivan, S. et al., Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat. Protoc. 2011, 6, 147-157.
25. Diamond, D. L., Syder, A. J., Jacobs, J. M., Sorensen, C. M. et al., Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog. 2010, 6, e1000719.
26. Fillebeen, C., Rivas-Estilla, A. M., Bisaillon, M., Ponka, P. et al., Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J. Biol. Chem. 2005, 280, 9049-9057.
27. Fillebeen, C., Pantopoulos, K., Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. J. Hepatol. 2010, 53, 995-999.
28. Koukoulis, G. K., Shen, J., Virtanen, I., Gould, V. E., Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum. Pathol. 2001, 32, 1356-1362.
29. Kobayashi, J., Yamada, S., Kawasaki, H., Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease. Hepatology 1994, 20, 1412-1417.
30. Inuzuka, S., Ueno, T., Torimura, T., Tamaki, S. et al., Vitronectin in liver disorders: biochemical and immunohistochemical studies. Hepatology 1992, 15, 629-636.
31. Paradis, V., Degos, F., Dargère, D., Pham, N. et al., Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005, 41, 40-47.
32. Hayman, E. G., Pierschbacher, M. D., Ohgren, Y., Ruoslahti, E., Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc. Natl. Acad. Sci. USA 1983, 80, 4003-4007.
33. Seiffert, D., Constitutive and regulated expression of vitronectin. Histol. Histopathol. 1997, 12, 787-797.
34. Schvartz, I., Seger, D., Shaltiel, S., Vitronectin. Int. J. Biochem. Cell Biol. 1999, 31, 539-544.
35. Zhou, X., Murphy, F. R., Gehdu, N., Zhang, J. et al., Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem. 2004, 279, 23996-24006.
36. Patsenker, E., Popov, Y., Wiesner, M., Goodman, S. L., Schuppan, D., Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J. Hepatol. 2007, 46, 878-887.
37. Patsenker, E., Popov, Y., Stickel, F., Schneider, V. et al., Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50, 1501-1511.
38. Edwards, S., Lalor, P. F., Tuncer, C., Adams, D. H., Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br. J. Cancer 2006, 95, 1545-1554.
39. Furutani, T., Hino, K., Okuda, M., Gondo, T. et al., Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006, 130, 2087-2098.
40. Nishina, S., Korenaga, M., Hidaka, I., Shinozaki, A. et al., Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. Liver. Int. 2010, 30, 683-692.
41. Franchini, M., Targher, G., Capra, F., Montagnana, M., Lippi, G., The effect of iron depletion on chronic hepatitis C virus infection. Hepatol. Int. 2008, 2, 335-340.